Cipterbin (inetetamab)

P2, N=32, Not yet recruiting, HenanCancerHospital; HenanCancerHospital

The combination of inetetamab, camrelizumab, and utidelone demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with HER2-positive MBC. These findings support this regimen as a viable treatment option in this setting and warrant further investigation in randomized controlled trials.

P2/3, N=268, Not yet recruiting, Fudan University

Patients previously treated with trastuzumab without HER2-TKIs had longer median PFS than those with prior TKI exposure (12.8 vs 5.7 months; P = 0.001). No treatment-related deaths were reported.ConclusionInetetamab-based regimens have shown promising efficacy and are well-tolerated for patients with HER2-positive MBC. These anti-HER2 regimens could be considered an alternative treatment option for this disease.

The most frequently combined chemotherapy was vinorelbine (83/90,92.2%). The most frequently concomitant targeted drug was pyrotinib (70/90,77.8%)...Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.

They were treated with a combination of Inetetamab, Tislelizumab, and the XELOX regimen (Inetetamab 300mg administered on Day 1; Tislelizumab 200mg administered on Day 1; Oxaliplatin 150mg administered on Day 2; Capecitabine 1.5g orally twice daily on Days 1-14; repeated every 3 weeks per cycle). The findings of this study suggest a novel first-line treatment strategy for advanced gastric cancer, potentially improving treatment efficacy and quality of life for HER2-positive gastric cancer patients. Nevertheless, further clinical trials are warranted to validate the efficacy and safety of this treatment approach.

No severe TAAEs were observed during the investigation. The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.

After treatment with erebulin, carboplatin and inetetamab sensitive revealed by the organoid drug sensitivity testing, partial response in lung metastasis and stable disease in liver metastasis were achieved. This typical case suggests that for the individual patients with advanced refractory breast cancer, especially those exhausting the standard treatment options, the PDOs may serve as an effective model for assessing individual drug sensitivity to optimize treatment decisions and improve treatment response.

P=N/A, N=30, Not yet recruiting, Shanghai Geriatric Medical Center; Shanghai Geriatric Medical Center

P2, N=48, Recruiting, Fudan University

The most common all-grade AEs were neutropenia (182/500, 36.4%) and leukopenia (157/500, 31.4%). Inetetamab was promising in HER2-positive MBC patients who had prior exposure to trastuzumab, offering a new option for patients with a prior failure of trastuzumab.

P4, N=47, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center